Table 1.
Characteristics of patients at baseline.
| Characteristics | Cohort A (N = 8) | Cohort B (N = 9) | P value |
|---|---|---|---|
| Age,y; median (Range) | 66 (53-73) | 58 (42-71) | 0.18 |
| Sex (male/ female) | 4/4 | 5/4 | 1 |
| Smoking status | 0.58 | ||
| Current/former | 2 (25) | 1 (11.1) | |
| Never | 6 (75) | 8 (88.9) | |
| ECOG PS (at initiation of ICI/chemotherapy) | 0.58 | ||
| 0 | 2 (25) | 1 (11.1) | |
| 1 | 6 (75) | 8 (88.9) | |
| Disease status | 0.47 | ||
| III B | 1 (12.5) | 0 | |
| IV | 7 (87.5) | 9 (100) | |
| Site of metastasis (at initiation of ICI/chemotherapy) | |||
| Brain | 3 (37.5) | 4 (44.4) | 1 |
| Liver | 3 (37.5) | 2 (22.2) | 0.62 |
| EGFR mutation status (initial biopsy/pre-TKI) | 1 | ||
| Del19 | 5 (62.5) | 6 (66.7) | |
| L858R | 3 (37.5) | 3 (33.3) | |
| T790M status (rebiopsy/post-TKI) | 0.64 | ||
| Positive | 5 (62.5) | 4 (44.4) | |
| Negative | 3 (37.5) | 5 (55.6) | |
| Prior treatment lines | 0.57 | ||
| 1 | 2 (25) | 2 (22.2) | |
| 2 | 3 (37.5) | 6 (66.7) | |
| 3 | 3 (37.5) | 1 (11.1) | |
| PD-L1 TPS | 0.11 | ||
| <1% | 3 (37.5) | 3 (33.3) | |
| 1-49% | 4 (50) | 0 | |
| ≥50% | 1 (12.5) | 3 (33.3) | |
| Unknown | 0 | 3 (33.3) |
ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor gene; ICI, immune checkpoint inhibitor; TKI, tyrosine kinase inhibitor; Del19, exon 19 deletions; PD-L1 TPS, programmed death-ligand 1 tumor proportion score.